Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 8/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656064 | 0.95 | SLC6A5 (0.45) | SSTR4SLC6A5SSTR1 | |
| SCHEMBL30656343 | 0.86 | CFD (0.36) | DRD2DRD3 | |
| SCHEMBL30656001 | 0.85 | RAB9A (0.45) | BTK | |
| SCHEMBL30656233 | 0.85 | SSTR4 (0.37) | SSTR4SSTR1 | |
| SCHEMBL30656331 | 0.83 | ALDH1A1 (0.38) | — | |
| SCHEMBL30656170 | 0.82 | HPGDS (0.40) | — | |
| SCHEMBL30656320 | 0.82 | SLC6A5 (0.49) | SLC6A5BTK | |
| SCHEMBL30714709 | 0.81 | SSTR4 (0.43) | SSTR4SLC6A5SSTR1CHRNB2CHRNB4 | |
| SCHEMBL30656120 | 0.80 | SLC26A4 (0.42) | — | |
| SCHEMBL31350334 | 0.79 | CD38 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | claimed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | claimed |
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | claimed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | SSTR4 3184/4885SLC6A5 1270/4885SSTR1 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.